Immunic, Inc. (IMUX)
NASDAQ: IMUX · IEX Real-Time Price · USD
1.410
+0.040 (2.92%)
At close: Jul 19, 2024, 4:00 PM
1.372
-0.038 (-2.70%)
Pre-market: Jul 22, 2024, 9:14 AM EDT
Immunic Employees
Immunic had 77 employees as of December 31, 2023. The number of employees increased by 11 or 16.67% compared to the previous year.
Employees
77
Change (1Y)
11
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,271,740
Market Cap
127.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 416 |
| Agenus | 389 |
| Veru Inc. | 189 |
| X4 Pharmaceuticals | 93 |
| Athira Pharma | 67 |
| Compass Therapeutics | 32 |
| Relmada Therapeutics | 20 |
| Annovis Bio | 16 |
IMUX News
- 13 days ago - Immunic Appoints Jason Tardio as Chief Operating Officer and President - PRNewsWire
- 7 weeks ago - Immunic to Participate in Industry and Scientific Conferences in June - PRNewsWire
- 2 months ago - Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Immunic to Participate in Investor and Scientific Conferences in May - PRNewsWire
- 2 months ago - Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update - PRNewsWire
- 2 months ago - Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation - PRNewsWire
- 3 months ago - Immunic to Host MS R&D Day and Participate in Investor Conferences in April - PRNewsWire
- 4 months ago - Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States - PRNewsWire